Navigation Links
Roche Introduces CoaguChek Link Web Resource to Streamline Anticoagulation Management for Doctors and Patients
Date:11/8/2010

INDIANAPOLIS, Nov. 8, 2010 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) and Voluntis S.A. announced today the introduction of CoaguChek(R) Link, a versatile online resource that helps simplify and streamline the process of managing patients on anticoagulation therapy.

The web-based application gives patients who self-test their PT/INR (clotting time) a simple, convenient way to report their test results and gives doctors a single, secure site to access data to more effectively monitor and manage their patients on warfarin therapy. It is available to physicians who prescribe a patient self-testing program through CoaguChek Patient Services (CPS), an Independent Diagnostic Testing Facility that provides support services for physicians and their patients. The application is based on the Medpassport platform developed by Voluntis, a healthcare software company specializing in Patient Relationship Management.

"CoaguChek Link helps doctors and their patients stay connected so they can work together to manage the patient's anticoagulation therapy more effectively, whether the patient is at home or away," said Tim Huston, director of marketing, professional diagnostics at Roche Diagnostics Corporation. "It simplifies the process for everyone, facilitates better therapy management, and contributes to the goal of helping improve patient outcomes."

CoaguChek Link offers healthcare providers a convenient patient management resource, helping to simplify documentation and streamline office workflow so they can focus on patients that require follow-up care. Clinics and physician offices can use the application (coagucheklink.com) to quickly enroll patients with CPS, educate them about their therapy, view test results in real time through a password-protected portal, modify recommended test frequency or acceptable ranges for patient test results, and generally access the information needed to monitor and adjust a patient's anticoagulant therapy from anywhere. If a patient doesn't report results according to schedule or the results are outside of the range the doctor specifies, the system automatically flags it and the patient's healthcare provider and CPS clinical specialists are notified.

The patient portal of CoaguChek Link helps empower patients to take a more active role in their anticoagulation therapy. At their convenience, enrolled patients can simply log in to the site to report their test results, order supplies, update their profile information, or learn more about their own therapy and the importance of testing.

"CoaguChek Link will give our healthcare providers greater flexibility and an expanded range of options," said Howard Sams, director of business operations at CoaguChek Patient Services. "It will help streamline and simplify the process of monitoring test results, which can help free up physicians to focus on managing patient therapy more effectively."

"We are delighted to have the opportunity to contribute to the continued success of CoaguChek Patient Services in the USA," said Pierre Leurent, Founder and CEO of Voluntis. "This program exemplifies our vision for Voluntis solutions: leading-edge, proven and secure technologies that have the potential to help improve patient care."

About CoaguChek Patient ServicesCoaguChek Patient Services (CPS) is an Independent Diagnostic Testing Facility (IDTF) that provides comprehensive support services for healthcare providers and their anticoagulation patients who perform self-testing. CPS is part of Roche Insulin Delivery Systems, which is accredited by the Joint Commission and has received its Gold Seal of Approval™ for complying with the highest national standards for safety and quality of care.

About VoluntisVoluntis is a healthcare software company specialized in Patient Relationship Management (PRM), its flagship product is called Medpassport. Its mission is to empower healthcare organizations (pharmaceutical and medical companies, insurers and employers, healthcare service providers) to deliver outstanding patient monitoring and support services, using state-of-the-art information and communication technologies. Since 2003, Medpassport has been deployed in Europe and the USA, to manage over 550,000 patient records in over 15 therapeutic areas, including diabetes, respiratory and cardiovascular diseases, oncology, nutrition and sports medicine. Voluntis is a certified ISO 9001:2008 and ISO 13485:2003 company. Voluntis is headquartered in Paris, France, and has offices in Washington DC, USA. To learn more: www.voluntis.com/?lang=en.

About RocheHeadquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80,000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com or www.roche-diagnostics.us.

Coagucheklink.com does not provide automated treatment decisions and is not a substitute for professional medical advice.

All trademarks used or mentioned in this release are protected by law.For further information, please contact: RocheBetsy Cox Director, Corporate Communications

Roche Diagnostics Corporation

Indianapolis, IN, USA(317) 521-3911betsy.cox@roche.comVoluntisManon Chevassut / Gaelle Ryouq

Media Relations, Presse-Papiers Agency+33 (0)1 46 99 69 62manon.chevassut@pressepapiers.fr / gaelle.ryouq@pressepapiers.fr
'/>"/>

SOURCE Roche Diagnostics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Rochester Medical Reports Fourth Quarter and Year-End Results
2. VIDEO from thenewsmarket.com and Roche Pharmaceuticals: MabThera Approved in Europe for First Line Maintenance Treatment of Follicular Lymphoma, a Common Type of Blood Cancer
3. Roche Introduces Immunoassay Module for cobas® 8000 Modular Analyzer Series In U.S.
4. Rochester Medical Announces Fourth Quarter 2010 Earnings Conference Call Thursday, November 4, 2010
5. Roche Receives FDA Approval for a Second-Generation Hepatitis C Viral Load Test
6. Roche Acquires RALS IT Connectivity Assets to Strengthen Presence in Point-of-Care Information Management
7. Roche and German Cancer Research Center (DKFZ) Enter Research Agreement to Predict Cervical Cancer
8. Roche Diagnostics Supports Fight Against MRSA as a Sponsor of Annual World MRSA Day
9. Roche Receives FDA Approval for Second-Generation Hepatitis B Viral Load Test
10. AstraZeneca Joins Rochester Initiative to Further Cardiac Safety
11. Roche Launches New Initiative - Roche Goes to Town
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... HANOVER, N.J. , April 19, 2017 /PRNewswire/ ... conducted by the National Heart, Lung, and Blood ... (NIH) demonstrating that 58% of patients with treatment-naïve ... six months when treated with eltrombopag at the ... 1 . The study evaluated three sequential treatment ...
Breaking Medicine Technology:
(Date:4/28/2017)... , ... April 28, 2017 , ... ... been previously exposed to more adverse experiences than children in the general population. ... such as abuse, neglect or other family challenges. While no fault of their ...
(Date:4/28/2017)... ... April 28, 2017 , ... Early detection and ... drug safety and minimize the cost of development. In this webinar, sponsored by ... cell lines and for cardiac toxicity using induced pluripotent stem cells (iPSCs). , ...
(Date:4/28/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has published a ... does not. Yisrayl says with so many titles and names for the Creator, it’s ... with a little Scripture, backed with a lot of research, the truth is undeniable. ...
(Date:4/28/2017)... ... April 28, 2017 , ... Intellitec Solutions announced the ... implement a Microsoft Dynamics GP solution that integrates to their PointClickCare EHR software ... in long-term care, Brooke Grove now has the capability to achieve its goal ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different ... purpose as the host of the “Informed” series. The program focuses on many important ... series focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of ...
Breaking Medicine News(10 mins):